OSE Immunotherapeutics SA (EPA: OSE)
France
· Delayed Price · Currency is EUR 8.89
+0.21 (2.42%)
Nov 22, 2024, 5:36 PM CET
OSE Immunotherapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 83.44 | 2.23 | 18.3 | 26.31 | 10.42 | 25.95 | Upgrade
|
| Other Revenue | - | - | - | - | 0 | - | Upgrade
|
| Revenue | 83.44 | 2.23 | 18.3 | 26.31 | 10.42 | 25.95 | Upgrade
|
| Revenue Growth (YoY) | 2209.49% | -87.83% | -30.43% | 152.48% | -59.85% | 6.12% | Upgrade
|
| Gross Profit | 83.44 | 2.23 | 18.3 | 26.31 | 10.42 | 25.95 | Upgrade
|
| Selling, General & Admin | 6.49 | 5.96 | 6.59 | 8.5 | 4.7 | 3.86 | Upgrade
|
| Research & Development | 21.32 | 17.09 | 26.82 | 30.49 | 22.31 | 21.62 | Upgrade
|
| Other Operating Expenses | 0.24 | 0.13 | 0.24 | 0.16 | 0.12 | 0.08 | Upgrade
|
| Operating Expenses | 29.6 | 25.21 | 36.78 | 42.93 | 29.41 | 27.42 | Upgrade
|
| Operating Income | 53.84 | -22.99 | -18.48 | -16.63 | -18.99 | -1.47 | Upgrade
|
| Interest Expense | -2.91 | -2.2 | -1.37 | -0.84 | -0.27 | -0.18 | Upgrade
|
| Interest & Investment Income | 0.59 | 0.34 | 0.02 | 0.01 | 0.01 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.07 | -0.04 | -0 | 0.04 | 0 | 0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.08 | 1.66 | 1.82 | 0.2 | -0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 49.37 | -23.23 | -18.02 | -17.22 | -19.25 | -1.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.07 | 0 | - | 0 | - | 0.07 | Upgrade
|
| Pretax Income | 49.44 | -23.22 | -18.02 | -17.21 | -19.25 | -1.46 | Upgrade
|
| Income Tax Expense | 3.41 | -0.22 | -0.26 | -0.36 | -2.69 | 3.19 | Upgrade
|
| Net Income | 46.03 | -23 | -17.76 | -16.85 | -16.56 | -4.65 | Upgrade
|
| Net Income to Common | 46.03 | -23 | -17.76 | -16.85 | -16.56 | -4.65 | Upgrade
|
| Shares Outstanding (Basic) | 21 | 20 | 19 | 18 | 16 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 20 | 19 | 18 | 16 | 15 | Upgrade
|
| Shares Change (YoY) | 22.97% | 5.58% | 2.05% | 16.71% | 4.46% | -4.03% | Upgrade
|
| EPS (Basic) | 2.18 | -1.18 | -0.96 | -0.93 | -1.06 | -0.31 | Upgrade
|
| EPS (Diluted) | 2.01 | -1.18 | -0.96 | -0.93 | -1.06 | -0.31 | Upgrade
|
| Free Cash Flow | 58.32 | -19.78 | -18.53 | -10.39 | -19.76 | 8.8 | Upgrade
|
| Free Cash Flow Per Share | 2.55 | -1.01 | -1.00 | -0.57 | -1.27 | 0.59 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 64.52% | -1032.15% | -100.96% | -63.20% | -182.25% | -5.67% | Upgrade
|
| Profit Margin | 55.17% | -1032.91% | -97.04% | -64.05% | -158.89% | -17.93% | Upgrade
|
| Free Cash Flow Margin | 69.90% | -888.19% | -101.22% | -39.50% | -189.65% | 33.90% | Upgrade
|
| EBITDA | 52.96 | -22.66 | -15.68 | -14.66 | -18.72 | -1.24 | Upgrade
|
| EBITDA Margin | 63.46% | - | -85.68% | -55.71% | -179.63% | -4.78% | Upgrade
|
| D&A For EBITDA | -0.88 | 0.32 | 2.8 | 1.97 | 0.27 | 0.23 | Upgrade
|
| EBIT | 53.84 | -22.99 | -18.48 | -16.63 | -18.99 | -1.47 | Upgrade
|
| EBIT Margin | 64.52% | - | -100.96% | -63.20% | -182.25% | -5.67% | Upgrade
|
| Revenue as Reported | 2.23 | 2.23 | 18.3 | 26.31 | 10.43 | 25.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.